Psychedelic Drugs Market to Surge to USD 4.6 Billion by 2030, Driven by Therapeutic Potential and Rising Mental Health Awareness


Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market 2030 by Source, Drug Type, Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index & Regional Footprints" report has been added to ResearchAndMarkets.com's offering.

Bolstered by increasing recognition of their therapeutic benefits, the global psychedelic drugs market is projected to experience a formidable growth trajectory in the coming years. Advanced research spotlighting psychedelics' efficacy in treating various mental health disorders is anticipated to fuel the market's ascension from USD 3.6 billion in 2022 to an estimated USD 4.6 billion by 2030, expanding at a CAGR of 13.5% during the forecast period from 2023 to 2030.

Research indicates a paradigm shift in the perception and regulatory stance towards psychedelics as a promising medical intervention. The transformation is particularly pronounced in North America, which is expected to retain its dominant market position bolstered by proactive research, mental health initiatives, and an expanding patient population seeking innovative therapeutic modalities.

The kaleidoscope of influence driving this market comprises key industry names such as Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer Inc., among others. These players are at the forefront, propelling advancements and expanding the potential treatment landscape for conditions like depression, PTSD, and addiction.

Rising Consciousness Over Mental Health Plays Pivotal Role in Market Growth

The advancing public narrative around mental health and its challenges is a contributing factor to market development. Educational initiatives and advocacy are increasingly spotlighting the mental health crisis, fostering an environment where novel treatments, including psychedelic drugs, are being explored and adopted.

Europe's Emergence in Psychedelic Drugs Market

Europe stands as the second most significant region in the global market, with Germany leading regional contributions. The region's growth mirrors a worldwide surge in demand for psychedelic substances, a trend sustained by robust investment in the research and development of new therapies.

Comprehensive insights into the Psychedelic Drugs Market highlight the strategic landscape and evolving competitive dynamics, with meticulous segmentation by source, drug type, indication, form, route of administration, end-user, and distribution channels. The report provides a granular examination of market strategies, corporate profiles, and ongoing progressions set to shape market opportunities and projections through to 2030.

Structured Insights into Psychedelic Drugs Market Dynamics

  • Market analysis by natural and synthetic source types
  • Detailed segmentation of drug types including GHB, Ketamine, Psilocybin, and LSD
  • Insight in different indications such as Depressive and Substance Abuse Disorders
  • Dissection by form, administration routes, and end-user demographics
  • Market trends and strategic opportunities within online and hospital pharmacies distribution channels

The Psychedelic Drugs Market report deliberates on the pressures and counterforces prevailing in the market, weighing the impact these factors may have over both immediate and long-term prospects. The collected intelligence supports businesses looking to strategically position themselves within the global market structure, while delineating avenues for heightened profitability and market share consolidation.

As mental health awareness ascends and psychedelic therapies garner more validation, the Psychedelic Drugs Market promises a bedrock of opportunities, capable of transforming the therapeutic landscape and offering new hope to millions affected by mental health disorders.

Companies Mentioned

  • Jazz Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals
  • Pfizer Inc.
  • Pfizer Inc.
  • Avadel
  • Celon Pharma S.A.
  • COMPASS
  • F. Hoffmann-La Roche Ltd
  • Hikma Pharmaceuticals PLC
  • NeuroRx, Inc.
  • PharmaTher Inc.
  • Mind Medicine, Inc.
  • Cybin Corp.
  • GABA Therapeutics, Inc.
  • EmpathBio
  • DemeRx

For more information about this report visit https://www.researchandmarkets.com/r/z70eec

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data